Experimental Medication For the Treatment of Generalized Anxiety Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00097708|
Recruitment Status : Completed
First Posted : November 30, 2004
Results First Posted : October 3, 2014
Last Update Posted : October 3, 2014
|Condition or disease||Intervention/treatment||Phase|
|Anxiety Disorder||Drug: experimental anti-anxiety drug||Phase 3|
The primary objective of the study is to assess, under controlled conditions, the safety and efficacy of an experimental anti-anxiety medication relative to placebo in subjects with generalized anxiety disorder (GAD).
The secondary objective of the study is to study algorithms for discontinuation of an experimental anti-anxiety medication.
Recruiting: Participants are currently being recruited and enrolled.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||511 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Double-Blind, Placebo Controlled Trial of an Experimental Medication For the Treatment of Generalized Anxiety Disorder|
|Study Start Date :||November 2004|
|Study Completion Date :||December 2005|
- Change in HAM-A Total Score [ Time Frame: Baseline to week 8 ]Hamilton Anxiety Rating Scale (HAM-A). Each of 14 symptoms categories is rated from 0=not present to 4=very severe. Numbers for all categories are summed to produce the total score. Total score ranges from 0=anxiety symptoms not present to 56=very severe anxiety symptoms across all 14 categories.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00097708
|Study Chair:||Murray Stein, MD||University of California, San Diego|